Stryker Corporation – Consensus Indicates Potential 4.9% Upside

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Stryker Corporation which can be found using ticker (SYK) now have 22 market analysts covering the stock. The analyst consensus now points to a rating of ‘Buy’. The target price High/Low ranges between 292 and 250 and has a mean target at $279.68. Now with the previous closing price of $266.71 and the analysts are correct then we can expect a percentage increase in value of 4.9%. It’s also worth noting that there is a 50 day moving average of $261.85 while the 200 day moving average is $228.60. The company has a market capitalization of $104,440m. You can visit the company’s website by visiting: https://www.stryker.com

The potential market cap would be $109,519m based on the market consensus.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

The company has a dividend yield of 1.12% with the ex dividend date set at 30-3-2023 (DMY).

Other points of data to note are a P/E ratio of 44.97, revenue per share of 48.78 and a 6.18% return on assets.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

      Search

      Search